HPV and cervical cancer
Abstract In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervica...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of clinical & laboratory investigation. Supplement Jg. 74; H. S244; S. 59 - 62 |
|---|---|
| 1. Verfasser: | |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Norway
Informa Healthcare
01.08.2014
Taylor & Francis |
| Schlagworte: | |
| ISSN: | 0036-5513, 2166-1030, 1502-7686, 2166-1030 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Abstract
In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervical cancer depends essentially on an infection of the uterine cervix with human papillomavirus (HPV) that needs to persist for many years and decades. Oncogenic cell transformation occurs almost exclusively in a discrete cell population at the squamous columnar junction (SCJ). These peculiarities enable primary prevention with HPV-vaccination as well as secondary prevention by detecting and treating true precursor lesions.
The actual screening program with annual cytology smears is already effective but results in a high number of false positive results and unnecessary treatments. Based on a good understanding of the etiology and high evidence from large randomized controlled trials a significant improvement in the prevention of cervical cancer by shifting to HPV screening in women aged 30 years or older is feasible. This would result in a further reduction of new cancer cases by 70-80 % with less screening examinations and interventions when well-defined patient pathways are followed and colposcopy in accordance with international quality standards is used as the gold standard for the minimal invasive management of abnormal findings. HPV vaccination prevents the development of approximately 80 % of true precursors and should have a similar impact on the incidence of cervical cancer. A combination of HPV vaccination and screening could almost eradicate cervical cancer and reduce the burden of other tumors and diseases related to HPV. |
|---|---|
| AbstractList | In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervical cancer depends essentially on an infection of the uterine cervix with human papillomavirus (HPV) that needs to persist for many years and decades. Oncogenic cell transformation occurs almost exclusively in a discrete cell population at the squamous columnar junction (SCJ). These peculiarities enable primary prevention with HPV-vaccination as well as secondary prevention by detecting and treating true precursor lesions. The actual screening program with annual cytology smears is already effective but results in a high number of false positive results and unnecessary treatments. Based on a good understanding of the etiology and high evidence from large randomized controlled trials a significant improvement in the prevention of cervical cancer by shifting to HPV screening in women aged 30 years or older is feasible. This would result in a further reduction of new cancer cases by 70-80 % with less screening examinations and interventions when well-defined patient pathways are followed and colposcopy in accordance with international quality standards is used as the gold standard for the minimal invasive management of abnormal findings. HPV vaccination prevents the development of approximately 80 % of true precursors and should have a similar impact on the incidence of cervical cancer. A combination of HPV vaccination and screening could almost eradicate cervical cancer and reduce the burden of other tumors and diseases related to HPV.In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervical cancer depends essentially on an infection of the uterine cervix with human papillomavirus (HPV) that needs to persist for many years and decades. Oncogenic cell transformation occurs almost exclusively in a discrete cell population at the squamous columnar junction (SCJ). These peculiarities enable primary prevention with HPV-vaccination as well as secondary prevention by detecting and treating true precursor lesions. The actual screening program with annual cytology smears is already effective but results in a high number of false positive results and unnecessary treatments. Based on a good understanding of the etiology and high evidence from large randomized controlled trials a significant improvement in the prevention of cervical cancer by shifting to HPV screening in women aged 30 years or older is feasible. This would result in a further reduction of new cancer cases by 70-80 % with less screening examinations and interventions when well-defined patient pathways are followed and colposcopy in accordance with international quality standards is used as the gold standard for the minimal invasive management of abnormal findings. HPV vaccination prevents the development of approximately 80 % of true precursors and should have a similar impact on the incidence of cervical cancer. A combination of HPV vaccination and screening could almost eradicate cervical cancer and reduce the burden of other tumors and diseases related to HPV. Abstract In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervical cancer depends essentially on an infection of the uterine cervix with human papillomavirus (HPV) that needs to persist for many years and decades. Oncogenic cell transformation occurs almost exclusively in a discrete cell population at the squamous columnar junction (SCJ). These peculiarities enable primary prevention with HPV-vaccination as well as secondary prevention by detecting and treating true precursor lesions. The actual screening program with annual cytology smears is already effective but results in a high number of false positive results and unnecessary treatments. Based on a good understanding of the etiology and high evidence from large randomized controlled trials a significant improvement in the prevention of cervical cancer by shifting to HPV screening in women aged 30 years or older is feasible. This would result in a further reduction of new cancer cases by 70-80 % with less screening examinations and interventions when well-defined patient pathways are followed and colposcopy in accordance with international quality standards is used as the gold standard for the minimal invasive management of abnormal findings. HPV vaccination prevents the development of approximately 80 % of true precursors and should have a similar impact on the incidence of cervical cancer. A combination of HPV vaccination and screening could almost eradicate cervical cancer and reduce the burden of other tumors and diseases related to HPV. In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervical cancer depends essentially on an infection of the uterine cervix with human papillomavirus (HPV) that needs to persist for many years and decades. Oncogenic cell transformation occurs almost exclusively in a discrete cell population at the squamous columnar junction (SCJ). These peculiarities enable primary prevention with HPV-vaccination as well as secondary prevention by detecting and treating true precursor lesions. The actual screening program with annual cytology smears is already effective but results in a high number of false positive results and unnecessary treatments. Based on a good understanding of the etiology and high evidence from large randomized controlled trials a significant improvement in the prevention of cervical cancer by shifting to HPV screening in women aged 30 years or older is feasible. This would result in a further reduction of new cancer cases by 70-80 % with less screening examinations and interventions when well-defined patient pathways are followed and colposcopy in accordance with international quality standards is used as the gold standard for the minimal invasive management of abnormal findings. HPV vaccination prevents the development of approximately 80 % of true precursors and should have a similar impact on the incidence of cervical cancer. A combination of HPV vaccination and screening could almost eradicate cervical cancer and reduce the burden of other tumors and diseases related to HPV. In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are increasing constantly although this tumor is one of the best preventable malignancies of all relevant human cancers. The genesis of cervical cancer depends essentially on an infection of the uterine cervix with human papillomavirus (HPV) that needs to persist for many years and decades. Oncogenic cell transformation occurs almost exclusively in a discrete cell population at the squamous columnar junction (SCJ). These peculiarities enable primary prevention with HPV-vaccination as well as secondary prevention by detecting and treating true precursor lesions. The actual screening program with annual cytology smears is already effective but results in a high number of false positive results and unnecessary treatments. Based on a good understanding of the etiology and high evidence from large randomized controlled trials a significant improvement in the prevention of cervical cancer by shifting to HPV screening in women aged 30 years or older is feasible. This would result in a further reduction of new cancer cases by 70-80 % with less screening examinations and interventions when well-defined patient pathways are followed and colposcopy in accordance with international quality standards is used as the gold standard for the minimal invasive management of abnormal findings. HPV vaccination prevents the development of approximately 80 % of true precursors and should have a similar impact on the incidence of cervical cancer. A combination of HPV vaccination and screening could almost eradicate cervical cancer and reduce the burden of other tumors and diseases related to HPV. |
| Author | Petry, Karl Ulrich |
| Author_xml | – sequence: 1 givenname: Karl Ulrich surname: Petry fullname: Petry, Karl Ulrich email: kupet@aol.com, kupet@aol.com organization: Department of Gynaecology and Obstetrics |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25083895$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkEtLAzEURoNU7EPXbkS6dDM1r3m5UKT4goIu1G1IMwlNSZOazCj992aYVtBFXd1cON_HzRmCnnVWAnCG4IQgWF5CSLI0RWSCIaKTkmRZQQ7AAKUQJ3lWZD0waJGkZfpgGMISxp0U9Aj0cQoLUpTpAJw-vryPua3GQvpPLbgZC27j-xgcKm6CPNnOEXi7v3udPiaz54en6e0sETSjdYIRpkgoXOZl7INUpRKmvBQqz8u5onmuEBdIZIhWEpUVIQQjNRekkpLwSiEyAhdd79q7j0aGmq10ENIYbqVrAkPt-TgvKIzo-RZt5itZsbXXK-43bPeZCNAOEN6F4KX6QRBkrTO2c8ZaZ6xzFmNXf2JC17zWztaea_Nf-KYLa6ucX_Ev503Far4xzisfVerQpvc2XP9qWEhu6oXgXrKla7yN9vef8A39k5Qz |
| CitedBy_id | crossref_primary_10_1002_ddr_21408 crossref_primary_10_3390_antiox13091143 crossref_primary_10_3892_ol_2018_8908 crossref_primary_10_1002_jmv_24899 crossref_primary_10_1063_5_0266298 crossref_primary_10_1155_2020_3670309 crossref_primary_10_1016_j_mtbio_2025_102127 crossref_primary_10_1080_21645515_2025_2513708 crossref_primary_10_3389_fonc_2022_858164 crossref_primary_10_1080_1061186X_2022_2107651 crossref_primary_10_1038_s44298_024_00087_5 crossref_primary_10_2174_0929867327666200128105459 crossref_primary_10_3390_biomedicines7040078 crossref_primary_10_1007_s12032_024_02446_x crossref_primary_10_1177_10732748221076813 crossref_primary_10_3389_fonc_2025_1567305 crossref_primary_10_1002_jgm_3212 crossref_primary_10_1016_j_critrevonc_2025_104736 crossref_primary_10_3390_molecules29050922 crossref_primary_10_1136_ijgc_2020_001254 crossref_primary_10_3892_mmr_2017_6378 crossref_primary_10_1038_s41420_018_0096_8 crossref_primary_10_1038_s41598_025_14823_1 crossref_primary_10_3389_fpubh_2023_1243539 crossref_primary_10_3390_v10120729 crossref_primary_10_1002_cam4_2040 crossref_primary_10_1088_1748_605X_ad3311 crossref_primary_10_3390_biology12070941 crossref_primary_10_3390_life10110290 crossref_primary_10_1007_s00404_018_5007_y crossref_primary_10_17116_repro20212701133 crossref_primary_10_5306_wjco_v16_i5_102456 crossref_primary_10_1016_j_puhip_2022_100274 crossref_primary_10_1016_j_meegid_2019_04_008 crossref_primary_10_1097_MD_0000000000017087 crossref_primary_10_1186_s13027_023_00488_w crossref_primary_10_1002_jcp_27109 crossref_primary_10_31083_j_ceog4806218 crossref_primary_10_3389_fonc_2022_904790 crossref_primary_10_3892_ol_2015_3849 crossref_primary_10_1186_s12889_019_6401_5 crossref_primary_10_1002_slct_202501153 crossref_primary_10_1371_journal_pgph_0004800 crossref_primary_10_1016_j_ijans_2023_100587 crossref_primary_10_1016_j_cca_2019_03_002 crossref_primary_10_1186_s12885_019_5286_0 crossref_primary_10_3390_cimb46060370 crossref_primary_10_3389_fcimb_2022_955847 crossref_primary_10_1002_rmv_1825 |
| Cites_doi | 10.1186/1471-2334-13-135 10.1016/j.ejogrb.2013.06.032 10.1016/S1386-6532(09)70294-X 10.1016/S1470-2045(11)70287-X 10.1016/S0140-6736(13)62218-7 10.1093/annonc/mdr015 10.1016/S0002-9378(99)70256-5 10.1016/S1470-2045(11)70078-X 10.1016/S0140-6736(11)60551-5 10.1016/j.vaccine.2012.06.095 10.1073/pnas.1202684109 10.1016/S0140-6736(12)60919-2 10.1093/eurpub/cki163 |
| ContentType | Journal Article |
| Copyright | 2014 Informa Healthcare 2014 |
| Copyright_xml | – notice: 2014 Informa Healthcare 2014 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.3109/00365513.2014.936683 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1502-7686 2166-1030 |
| EndPage | 62 |
| ExternalDocumentID | 25083895 10_3109_00365513_2014_936683 936683 |
| Genre | Research Article Journal Article |
| GroupedDBID | --- -~X .55 .GJ 00X 03L 08R 0BK 0R~ 123 34G 36B 39C 3O- 4.4 53G 5RE 5VS AAJNR AALIY AALUX AAMIU AAPUL AAPXX AAQQT AAQRR AAUGY AAWTL ABBKH ABDBF ABEIZ ABLJU ABLKL ABOCM ABPTK ABUPF ABWCV ABZEW ACENM ACFUF ACGEJ ACGFS ACKZS ACLSK ADCVX ADFCX ADFOM ADFZZ ADRBQ ADXPE AECIN AEIIZ AENEX AEOZL AEYQI AFFNX AFKVX AFLEI AFWLO AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJVHN AJWEG AKBVH ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AMDAE AWYRJ BABNJ BLEHA BOHLJ BRMBE CAG CCCUG COF CS3 CYYVM CZDIS DKSSO DRXRE DU5 DWTOO EAP EAS EBB EBC EBD EBS EBX EHN EJD EMB EMK EMOBN EPL EPT ESX F5P H13 HZ~ J.N JENTW KRBQP KSSTO KWAYT KYCEM L7B LJTGL M44 M4Z O9- OVD P2P QQXMO Q~Q RNANH RVRKI SV3 TEORI TFDNU TFL TFW TUS UEQFS UHWXJ V1S WH7 X7M ZA5 ZGI ZXP ~1N AAGDL ABJNI ABLIJ ABWVI ABXYU ACIEZ ACUHS AFRVT ALYBC AQTUD TASJS TBQAZ TDBHL TERGH TUROJ AAJKZ AAORF AAYXX ACOPL ACYZI CITATION NUSFT 04C ADBBV BMSDO CGR CUY CVF ECM EIF EIHBH MK0 NPM 7X8 |
| ID | FETCH-LOGICAL-c464t-21241cf297938904f5e05a9cf779bf477f1ac1c614de19d33321fbc3dee3adf13 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 74 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000340459300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0036-5513 2166-1030 |
| IngestDate | Tue Oct 21 13:22:32 EDT 2025 Wed Feb 19 02:15:27 EST 2025 Sat Nov 29 02:41:36 EST 2025 Tue Nov 18 22:51:23 EST 2025 Mon Oct 20 23:39:28 EDT 2025 Wed Jun 21 08:18:38 EDT 2023 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | S244 |
| Keywords | screening Vaccination human papilloma virus |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c464t-21241cf297938904f5e05a9cf779bf477f1ac1c614de19d33321fbc3dee3adf13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.3109/00365513.2014.936683?needAccess=true&role=button |
| PMID | 25083895 |
| PQID | 1551327840 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | pubmed_primary_25083895 proquest_miscellaneous_1551327840 informahealthcare_journals_10_3109_00365513_2014_936683 crossref_primary_10_3109_00365513_2014_936683 informaworld_taylorfrancis_310_3109_00365513_2014_936683 crossref_citationtrail_10_3109_00365513_2014_936683 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-08-01 |
| PublicationDateYYYYMMDD | 2014-08-01 |
| PublicationDate_xml | – month: 08 year: 2014 text: 2014-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Norway |
| PublicationPlace_xml | – name: Norway |
| PublicationTitle | Scandinavian journal of clinical & laboratory investigation. Supplement |
| PublicationTitleAlternate | Scand J Clin Lab Invest Suppl |
| PublicationYear | 2014 |
| Publisher | Informa Healthcare Taylor & Francis |
| Publisher_xml | – name: Informa Healthcare – name: Taylor & Francis |
| References | Liebrich C (CIT0005) 2009; 30 Parkin DM (CIT0003) 2006; 24 Moss EL (CIT0015) 2013; 170 Brotherton JM (CIT0009) 2011; 377 Arbyn M (CIT0002) 2011; 22 Kocken M (CIT0010) 2011; 12 Siebert U (CIT0011) 2006; 16 Arbyn M (CIT0012) 2012; 30 Luyten A (CIT0016) 2009; 46 Petry KU (CIT0007) 2013; 13 Wheeler CM (CIT0008) 2012; 13 Ronco G (CIT0013) 2014; 383 Soerjomataram I (CIT0001) 2012; 380 CIT0004 Herfs M (CIT0006) 2012; 109 |
| References_xml | – volume: 13 start-page: 135 year: 2013 ident: CIT0007 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-13-135 – volume: 24 start-page: S3 issue: 3 year: 2006 ident: CIT0003 publication-title: Vaccine – volume: 170 start-page: 255 year: 2013 ident: CIT0015 publication-title: Eur J Obstet Gynecol Reprod Biol doi: 10.1016/j.ejogrb.2013.06.032 – volume: 46 start-page: S5 issue: 3 year: 2009 ident: CIT0016 publication-title: J Clin Virol doi: 10.1016/S1386-6532(09)70294-X – volume: 30 start-page: 45 year: 2009 ident: CIT0005 publication-title: Eur J Gynaecol Oncol – volume: 13 start-page: 100 year: 2012 ident: CIT0008 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70287-X – volume: 383 start-page: 524 year: 2014 ident: CIT0013 publication-title: Lancet doi: 10.1016/S0140-6736(13)62218-7 – volume: 22 start-page: 2675 year: 2011 ident: CIT0002 publication-title: Ann Oncol doi: 10.1093/annonc/mdr015 – ident: CIT0004 doi: 10.1016/S0002-9378(99)70256-5 – volume: 12 start-page: 441 year: 2011 ident: CIT0010 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70078-X – volume: 377 start-page: 2085 year: 2011 ident: CIT0009 publication-title: Lancet doi: 10.1016/S0140-6736(11)60551-5 – volume: 30 start-page: F88 issue: 5 year: 2012 ident: CIT0012 publication-title: Vaccine doi: 10.1016/j.vaccine.2012.06.095 – volume: 109 start-page: 10516 year: 2012 ident: CIT0006 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1202684109 – volume: 380 start-page: 1840 year: 2012 ident: CIT0001 publication-title: Lancet doi: 10.1016/S0140-6736(12)60919-2 – volume: 16 start-page: 185 year: 2006 ident: CIT0011 publication-title: Eur J Public Health doi: 10.1093/eurpub/cki163 |
| SSID | ssj0003384 ssj0026105 |
| Score | 2.3230662 |
| Snippet | Abstract
In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases... In recent analyses of the global burden of cancer among women, cervical cancer ranked second to breast cancer. Numbers of new cervical cancer cases are... |
| SourceID | proquest pubmed crossref informaworld informahealthcare |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 59 |
| SubjectTerms | Early Detection of Cancer Female human papilloma virus Humans Papillomavirus Infections - diagnosis Papillomavirus Infections - epidemiology Papillomavirus Infections - prevention & control Prevalence screening Uterine Cervical Neoplasms - diagnosis Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - prevention & control Uterine Cervical Neoplasms - virology Vaccination |
| Title | HPV and cervical cancer |
| URI | https://www.tandfonline.com/doi/abs/10.3109/00365513.2014.936683 https://www.ncbi.nlm.nih.gov/pubmed/25083895 https://www.proquest.com/docview/1551327840 |
| Volume | 74 |
| WOSCitedRecordID | wos000340459300012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1502-7686 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0026105 issn: 0036-5513 databaseCode: TFW dateStart: 19510101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1502-7686 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003384 issn: 0036-5513 databaseCode: TFW dateStart: 19490101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwEA86RHzR-TXnx6jga2Vp0jZ5FHHsxbGHqXsLSZqgIFW2zr_fXNOWqcyBPrbkEq65y12ay--H0JWJcZIYE4cGiMIoUTaULk8OrbNlQ_rMEuLJJtLRiE2nfLx0ix_KKmEPbT1QRLlWg3NLVTKQAI4l8I8lwEsChVn0mpMkYQD36RJ7qOmbDJ6apdjtv2iNugsS_u7cyk6-xKZ2hVz63NRhfUMzXZ2TlrFpsPd_rdpot8pLgxtvSPtow-QHaPu-Onk_RJ3h-DFwfQe6XFxcUw32MjtCD4O7ye0wrEgVQk0TWoQuVFGsbcSdYzLepzY2_VhybdOUK0vT1GKpsXZROzOYZ4SQCFulSWYMkZnF5Bi18rfcnKCA4iyD15GMJZVYKgUbFsazSCtlEtVFpP6cQleI40B88SrczgN0FrXOAnQWXucuChupd4-4saZ9-mOmROWI8zWSbHk-RVH-I7Ge0ATEfhO9rOdeOH-EQxaZm7eFGxCawmluv4s63igaNSLA3mc8Pv37wGdoB558CeI5ahWzhblAW_qjeJnPemgznbJe6QOfff_7nQ |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT8MwDLZgIOAC4zXGc0hcC02TPnJEiGmIbdphwG5RmiYCCW1oD34_cdNNPDQmIa5tnNaNHdux-xngQockirQOPY2NwhhNjSetn-wZK8ua-omh1DWbiNvtpNfjnaKacFSUVWIMbRxQRL5Xo3LjYfRVHmL6HBuQRdiYBCuz2CWnUZTQZVixngBDUe_Wn2absY3A2BR3F0nc33NzZ_lincoFdunzrBLrG57pfK80t071rX_gqwybhWtau3aytA1Lur8Da60i-b4LlUbnsWYnr6l8f7FDFYrMcA8e6rfdm4ZX9FXwFIvY2LPWihFlAm51M-E-M6H2Q8mViWOeGhbHhkhFlDXcmSY8o5QGxKSKZlpTmRlC96HUH_T1AdQYyTK8HMhQMklkmmLMkvAsUGmqo7QKdPo9hSpAx7H3xauwwQfyLKY8C-RZOJ6r4M2o3hzoxoLx8Y-lEoUujhZQJp8XVIzzYxLjepog2W-k59PFF1YlMc8i-3owsQ_EoZjQ9atQcVIxYyNA-P2Eh4d_fuUzWG90W03RvGvfH8EG3nEFicdQGg8n-gRW1fv4ZTQ8zTXhAz1X_mo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8MwDLZgIMQFxmuM55C4FpomfeSIgGkImHYYsFuUpolAQtu0B7-fuOmmARqT4NrGad3YsV07nwHOdUiiSOvQ09gojNHUeNL6yZ6xsqypnxhKXbOJuNlMOh3emjnFj2WVGEMbBxSR79Wo3P3MXOYRps-x_1iEfUmwMItdcBpFCV2GlQi9cyvR7frLdC-2ARibwO4iiTs8N3eWL8apXECXvk4Lsb7Bmc53SnPjVN_8P1tl2Cgc09qVk6QtWNLdbVh7LFLvO1BptJ5rdu6ayncXO1ShwAx24al-275ueEVXBU-xiI08a6sYUSbgVjMT7jMTaj-UXJk45qlhcWyIVERZs51pwjNKaUBMqmimNZWZIXQPSt1eV-9DjZEsw8uBDCWTRKYpRiwJzwKVpjpKq0Ann1OoAnIcO1-8Cxt6IM9iwrNAnoXjuQrelKrvIDcWjI9_rJQoNHG4gDKZXU8xyn-SGNfRBMl-Iz2brL2wColZFtnVvbF9IA7FdK5fhYoTiikbAYLvJzw8-PMrn8Ja66YuHu6a94ewjjdcNeIRlEaDsT6GVfUxehsOTnI9-ARAvP0i |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HPV+and+cervical+cancer&rft.jtitle=Scandinavian+journal+of+clinical+%26+laboratory+investigation.+Supplement&rft.au=Petry%2C+Karl+Ulrich&rft.date=2014-08-01&rft.issn=2166-1030&rft.eissn=2166-1030&rft.volume=244&rft.spage=59&rft_id=info:doi/10.3109%2F00365513.2014.936683&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0036-5513&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0036-5513&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0036-5513&client=summon |